New drug combo targets hard-to-treat cancers with KRAS mutation
NCT ID NCT05358249
First seen Oct 31, 2025 · Last updated May 06, 2026 · Updated 22 times
Summary
This study tests a new drug called JDQ443, given alone or with other treatments, for people with advanced solid tumors that have a specific change in the KRAS gene (G12C). The goal is to find safe doses and see if the drug can shrink tumors. About 74 adults with lung or colorectal cancer that has not responded to standard treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NYU School of Medicine
New York, New York, 10015, United States
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
Conditions
Explore the condition pages connected to this study.